Nasal Glucagon + Intramuscular Glucagon
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Trial Timeline
Nov 10, 2017 → Jan 13, 2018
NCT ID
NCT03339453About Nasal Glucagon + Intramuscular Glucagon
Nasal Glucagon + Intramuscular Glucagon is a phase 1 stage product being developed by Eli Lilly for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03339453. Target conditions include Hypoglycemia, Diabetes Mellitus, Type 1.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03339453 | Phase 1 | Completed |
| NCT01994746 | Phase 3 | Completed |
| NCT01997411 | Phase 2/3 | Completed |
Competing Products
20 competing products in Hypoglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 1416 (INN imapextide) | MBX Biosciences | Phase 2 | 47 |
| MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C) | MBX Biosciences | Phase 1 | 28 |
| Nasal Glucagon | Eli Lilly | Phase 3 | 77 |
| Glucagon + Insulin | Abvance Therapeutics | Phase 1 | 25 |
| Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mg | Eli Lilly | Phase 2 | 52 |
| Nasal Glucagon | Eli Lilly | Phase 3 | 77 |
| Eplerenone + Placebo | Johnson & Johnson | Pre-clinical | 23 |
| Sitagliptin phosphate + Placebo | Merck | Approved | 85 |
| Pasireotide | Novartis | Phase 1 | 33 |
| Dasiglucagon | Novo Nordisk | Phase 3 | 76 |
| Glucagen + Mayne Glucagon | Pfizer | Phase 1 | 32 |
| Pramlintide | Bristol Myers Squibb | Approved | 84 |
| dasiglucagon + placebo + GlucaGen HypoKit | Zealand Pharma | Phase 3 | 74 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 1 | 30 |
| Dasiglucagon + Dasiglucagon + Placebo | Zealand Pharma | Phase 2 | 49 |
| ZP4207 + Glucagon | Zealand Pharma | Phase 1 | 30 |
| ZP4207 + Placebo | Zealand Pharma | Phase 1 | 30 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 3 | 74 |
| dasiglucagon + GlucaGen | Zealand Pharma | Phase 3 | 74 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 2 | 49 |